LOKAL İLERİ REZEKE EDİLEMEYEN VE METASTATİK MİDE KANSERİNDE TEDAVİ ÖNCESİ İNFLAMASYON YANITI BELİRTEÇLERİNİN SAĞKALIM ÜZERİNE ETKİSİ: RETROSPEKTİF CROSS-SECTIONALÇALIŞMA

Tolga Doğan, Arzu Yaren, A. G. Demi̇ray, Burcu YAPAR TAŞKÖYLÜ, Burçin ÇAKAN DEMİREL, Melek Özdemi̇r, Taliha GÜÇLÜ KANTAR, Serkan Deği̇rmenci̇oğlu, Gamze GOKOZ DOGU
{"title":"LOKAL İLERİ REZEKE EDİLEMEYEN VE METASTATİK MİDE KANSERİNDE TEDAVİ ÖNCESİ İNFLAMASYON YANITI BELİRTEÇLERİNİN SAĞKALIM ÜZERİNE ETKİSİ: RETROSPEKTİF CROSS-SECTIONALÇALIŞMA","authors":"Tolga Doğan, Arzu Yaren, A. G. Demi̇ray, Burcu YAPAR TAŞKÖYLÜ, Burçin ÇAKAN DEMİREL, Melek Özdemi̇r, Taliha GÜÇLÜ KANTAR, Serkan Deği̇rmenci̇oğlu, Gamze GOKOZ DOGU","doi":"10.31362/patd.1265291","DOIUrl":null,"url":null,"abstract":"Abstract \nPurpose:We evaluated the effect of pre-treatment inflammation response markers on overall survival (OS) and progression-free survival (PFS) in patients with locally advanced unresectable and metastatic gastric cancer. \nMaterial and Method:Patients with locally advanced unresectable and metastatic gastric cancer between January 2016 and December 2021 were included. Among these patients, 114 patients with ECOG (Eastern Cooperative Oncology Group) Performance status 0-2, who received at least one line of chemotherapy, had no comorbidities and brain metastases were included in the study. Pre-treatment platelet, lymphocyte, leukocyte, neutrophil, monocyte, albumin, C-reactive protein (CRP), lactatedehydrogenase (LDH) levels, histology types, age, surgical history, treatment history and ECOG Performance status were retrospectively analysed from their files. Threshold values of all values were determined by ROC analysis. Kaplan-Meier survival analyses were used for survival analyses. Hazardratio (HR) and confidence intervals (CI) of the factors affecting overall survival (OS) and progression-free survival (PFS) were calculated using Coxproportional-hazards model. \nResults:The median age of the patients was 63.5±11.9(28-80) years. Among the patients, 69(60.5%) were in metastatic stage. One hundred and six (93.0%) patients had poorly differentiated carcinoma histology. Progression developed in 88.6% (101) of patients and 98 patients (86%) were deceased. In the whole group, mPFS was 9.4+0.9 (95%CI 7.7-11.0) months and mOS was 14.1+1.6 (95%CI 10.8-17.2) months. When the Coxproportional-hazards model was used, the factors affecting OS were advanced age, metastatic stage, neutrophil lymphocyte ratio (NLR), platelet lymphocyte ratio (PLR), derived neutrophil lymphocyte ratio (dNLR) and lactate dehydrogenase (LDH), while the factors affecting PFS were advanced age, metastatic stage, NLR, dNLR and LDH. \nConclusion: While NLR, PLR, dNLR, dNLR and LDH affect OS, LDH affects PFS. Systemic inflammatory markers of locally advanced unresectable and metastatic gastric cancers before chemotherapy can be used to predict prognosis.","PeriodicalId":19789,"journal":{"name":"Pamukkale Medical Journal","volume":"93 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pamukkale Medical Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31362/patd.1265291","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Abstract Purpose:We evaluated the effect of pre-treatment inflammation response markers on overall survival (OS) and progression-free survival (PFS) in patients with locally advanced unresectable and metastatic gastric cancer. Material and Method:Patients with locally advanced unresectable and metastatic gastric cancer between January 2016 and December 2021 were included. Among these patients, 114 patients with ECOG (Eastern Cooperative Oncology Group) Performance status 0-2, who received at least one line of chemotherapy, had no comorbidities and brain metastases were included in the study. Pre-treatment platelet, lymphocyte, leukocyte, neutrophil, monocyte, albumin, C-reactive protein (CRP), lactatedehydrogenase (LDH) levels, histology types, age, surgical history, treatment history and ECOG Performance status were retrospectively analysed from their files. Threshold values of all values were determined by ROC analysis. Kaplan-Meier survival analyses were used for survival analyses. Hazardratio (HR) and confidence intervals (CI) of the factors affecting overall survival (OS) and progression-free survival (PFS) were calculated using Coxproportional-hazards model. Results:The median age of the patients was 63.5±11.9(28-80) years. Among the patients, 69(60.5%) were in metastatic stage. One hundred and six (93.0%) patients had poorly differentiated carcinoma histology. Progression developed in 88.6% (101) of patients and 98 patients (86%) were deceased. In the whole group, mPFS was 9.4+0.9 (95%CI 7.7-11.0) months and mOS was 14.1+1.6 (95%CI 10.8-17.2) months. When the Coxproportional-hazards model was used, the factors affecting OS were advanced age, metastatic stage, neutrophil lymphocyte ratio (NLR), platelet lymphocyte ratio (PLR), derived neutrophil lymphocyte ratio (dNLR) and lactate dehydrogenase (LDH), while the factors affecting PFS were advanced age, metastatic stage, NLR, dNLR and LDH. Conclusion: While NLR, PLR, dNLR, dNLR and LDH affect OS, LDH affects PFS. Systemic inflammatory markers of locally advanced unresectable and metastatic gastric cancers before chemotherapy can be used to predict prognosis.
目的:评估治疗前炎症反应标志物对局部晚期不可切除转移性胃癌患者总生存期(OS)和无进展生存期(PFS)的影响。材料和方法:纳入2016年1月至2021年12月的局部晚期不可切除转移性胃癌患者。在这些患者中,114例ECOG (Eastern Cooperative Oncology Group)表现状态为0-2、接受至少一条化疗线、无合并症且脑转移的患者纳入研究。回顾性分析治疗前患者的血小板、淋巴细胞、白细胞、中性粒细胞、单核细胞、白蛋白、c反应蛋白(CRP)、乳酸脱氢酶(LDH)水平、组织学类型、年龄、手术史、治疗史及ECOG表现情况。所有值的阈值均采用ROC分析确定。生存分析采用Kaplan-Meier生存分析。采用比例风险模型计算影响总生存期(OS)和无进展生存期(PFS)因素的风险比(HR)和置信区间(CI)。结果:患者中位年龄为63.5±11.9(28-80)岁。转移期69例(60.5%)。106例(93.0%)患者为低分化癌组织学。88.6%(101例)患者出现进展,98例(86%)患者死亡。全组mPFS为9.4+0.9 (95%CI 7.7 ~ 11.0)个月,mOS为14.1+1.6 (95%CI 10.8 ~ 17.2)个月。采用比例危害模型时,影响OS的因素为高龄、转移期、中性粒细胞淋巴细胞比(NLR)、血小板淋巴细胞比(PLR)、衍生性中性粒细胞淋巴细胞比(dNLR)和乳酸脱氢酶(LDH),影响PFS的因素为高龄、转移期、NLR、dNLR和LDH。结论:NLR、PLR、dNLR、dNLR和LDH影响OS, LDH影响PFS。化疗前局部晚期不可切除和转移性胃癌的全身炎症标志物可用于预测预后。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
0.20
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信